Merck Awarded its First CRISPR Patent by Australian Patent Office

摘要

Merck has announced that the Australian Patent Office has granted the company patent rights over the use of CRISPR in a genomic integration method for eukaryotic cells.The patent is the first that Merck has received for CRISPR technology.The patent covers chromosomal integration,or cutting of the chromosomal sequence of eukaryotic cells(such as mammalian and plant cells)and insertion of an external or donor DNA sequence into those cells using CRISPR.”Merck has developed an incredible tool to give scientists the ability to find new treatments and cures for conditions for which there are limited options,including cancer,rare diseases and chronic conditions,such as diabetes,”said Udit Batra,Member of the Merck Executive Board and CEO,Life Science.”This patent decision recognises our expertise in CRISPR technology-a body of knowledge that we are committed to grow.”